CPI-613 (devimistat) + FOLFIRINOX

About Rafael Holdings

Rafael Holdings is a clinical-stage biotech focused on developing novel oncology and rare disease therapeutics. Its core mission is to improve and extend the lives of patients with difficult-to-treat diseases by targeting cancer metabolism and lysosomal function. The company's strategy leverages its lead asset, devimistat, in late-stage trials for solid tumors and hematologic malignancies, while integrating new platforms through strategic mergers. With two Phase 3 trials ongoing and a recent expansion into rare diseases, Rafael is transitioning from a clinical-stage entity toward a potential commercial enterprise.

Therapeutic Areas